RxDoctor Payments Data

Melissa Hardesty, MD

Gynecologic Oncology · Anchorage, AKNPI 1821092362

Payments from drug & device makers

$663,522in general payments, 2019–2025

Across 424 payments — averaging $1564.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$203K
  • Alkermes, Inc.$188K
  • Daiichi Sankyo Inc.$84K
  • Incyte Corporation$74K
  • AstraZeneca$45K
  • GSK$31K
  • plus $39K from 17 others

What the payments were for

  • Consulting fees$71,60384%
  • Speaking & faculty fees$4,2705%
  • Travel & lodging$1,2992%
  • Food & beverage$4,0865%
  • Education$4,3315%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gynecologic oncology providers in Alaskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$147,545
Medicare patients
214
Services billed
554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib33$523,703
ZejulaNiraparib Tosylate17$321,123
XareltoRivaroxaban27$24,763
EliquisApixaban30$18,398
Prednisolone Acetate16$1,290
Estradiol22$1,271
Letrozole57$1,168
ComproProchlorperazine15$573
Omeprazole75$475
Gabapentin27$450
Ondansetron OdtOndansetron32$352
Prochlorperazine Maleate25$260
Dexamethasone59$214
Lidocaine-PrilocaineLidocaine/Prilocaine13$132
Oxycodone Hcl13$132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$45,494$523,70333 claims
GSKZejula$30,636$321,12317 claims
PfizerEliquis$91$18,39830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gynecologic oncology providers in Alaskaon file to place this against a meaningful peer group, so we don't.

Other gynecologic oncology in Anchorage

Where these figures come from

Is this you, or does something look wrong? →